Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging Co-signaling Networks in T Cell Immune Regulation
Keun‐Ok Jung, Inhak Choi
Immune Network (2013) Vol. 13, Iss. 5, pp. 184-184
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Daniel Sanghoon Shin, Antoni Ribas
Current Opinion in Immunology (2015) Vol. 33, pp. 23-35
Closed Access | Times Cited: 328
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li, Changshun Shao, Yufang Shi, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 321
Second- and third-generation drugs for immuno-oncology treatment—The more the better?
Wolfram C. M. Dempke, Klaus Fenchel, Peter Uciechowski, et al.
European Journal of Cancer (2017) Vol. 74, pp. 55-72
Closed Access | Times Cited: 218
Cancer Vaccines, Adjuvants, and Delivery Systems
Samantha Paston, Victoria A. Brentville, Peter Symonds, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 143
PD-1/PD-L1 Pathway in Breast Cancer
Florian Schütz, S Stefanović, Luisa Mayer, et al.
Oncology Research and Treatment (2017) Vol. 40, Iss. 5, pp. 294-297
Open Access | Times Cited: 162
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Sara Saab, Hussein Zalzale, Zahraa Rahal, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 96
Immunotherapy in breast cancer
Soley Bayraktar, Sameer Batoo, Scott H. Okuno, et al.
Journal of Carcinogenesis (2019) Vol. 18, Iss. 1, pp. 2-2
Open Access | Times Cited: 68
B7-H3 Immune Checkpoint Protein in Human Cancer
Karine Flem‐Karlsen, Øystein Fodstad, Caroline E. Nunes‐Xavier
Current Medicinal Chemistry (2019) Vol. 27, Iss. 24, pp. 4062-4086
Closed Access | Times Cited: 62
B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling
Sadiye Amcaoglu Rieder, Jingya Wang, Natalie White, et al.
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 6, pp. 1503-1511
Open Access | Times Cited: 57
The DNA replication regulator MCM6: An emerging cancer biomarker and target
Tian Zeng, Guan Yang, Yukun Li, et al.
Clinica Chimica Acta (2021) Vol. 517, pp. 92-98
Closed Access | Times Cited: 43
Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis
Jeffrey T. Guptill, Madhu Soni, Matthew N. Meriggioli
Neurotherapeutics (2015) Vol. 13, Iss. 1, pp. 118-131
Open Access | Times Cited: 60
PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies
Július Benický, Miloslav Šanda, Zuzana Brnakova Kennedy, et al.
Journal of Proteome Research (2020) Vol. 20, Iss. 1, pp. 485-497
Open Access | Times Cited: 42
The IFNγ-PDL1 Pathway Enhances CD8T-DCT Interaction to Promote Hypertension
Lance Benson, Yunmeng Liu, Xiangting Wang, et al.
Circulation Research (2022) Vol. 130, Iss. 10, pp. 1550-1564
Open Access | Times Cited: 27
KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
Yang Li, Chao Lv, Yang Yu, et al.
Journal of Advanced Research (2022) Vol. 47, pp. 137-150
Open Access | Times Cited: 23
Current status and future of cancer vaccines: A bibliographic study
Rui Yu, Fangmin Zhao, Zeting Xu, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24404-e24404
Open Access | Times Cited: 5
Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets
Tatiana Vilela, Sofia Valente, Jorge Correia, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189144-189144
Open Access | Times Cited: 5
Activation of the Arylhydrocarbon Receptor Causes Immunosuppression Primarily by Modulating Dendritic Cells
Anika Bruhs, Thomas Haarmann‐Stemmann, Katrin Frauenstein, et al.
Journal of Investigative Dermatology (2014) Vol. 135, Iss. 2, pp. 435-444
Open Access | Times Cited: 51
Checkpoint Inhibitors and Their Application in Breast Cancer
Davide Bedognetti, Cristina Maccalli, Salha B.J. Al Bader, et al.
Breast Care (2016) Vol. 11, Iss. 2, pp. 108-115
Open Access | Times Cited: 44
Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer
Zhenyu Xu, Jing Shen, Maggie Haitian Wang, et al.
OncoImmunology (2016) Vol. 5, Iss. 8, pp. e1207841-e1207841
Open Access | Times Cited: 39
Unraveling the Expression Patterns of Immune Checkpoints Identifies New Subtypes and Emerging Therapeutic Indicators in Lung Adenocarcinoma
Jinguo Zhang, Xinghua Han, Lin Lin, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-19
Open Access | Times Cited: 20
Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
Laura L. Michel, Alexandra von Au, Athanasios Mavratzas, et al.
Targeted Oncology (2020) Vol. 15, Iss. 4, pp. 415-428
Closed Access | Times Cited: 29
PD-1 related transcriptome profile and clinical outcome in diffuse gliomas
Shuai Liu, Zheng Wang, Yinyan Wang, et al.
OncoImmunology (2017) Vol. 7, Iss. 2
Open Access | Times Cited: 31
Inhibition of immune checkpoints prevents injury-induced heterotopic ossification
Kan Chen, Jiazhao Yang, Na Ding, et al.
Bone Research (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 27
Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets
Diana Tronik‐Le Roux, Mathilde Sautreuil, Mahmoud Bentriou, et al.
Cancer Immunology Immunotherapy (2020) Vol. 69, Iss. 7, pp. 1237-1252
Closed Access | Times Cited: 26
Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy
Honggang Ying, Jian Xu, Xiaozhen Zhang, et al.
EBioMedicine (2022) Vol. 79, pp. 103987-103987
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top